Hikma Pharmaceuticals (HKMPF) announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (EBS) for the sale of Kloxxado naloxone HCl nasal spray 8 mg in the U.S ...

NAD+ IonToPatch – Utilizing iontophoresis, a non-invasive transdermal drug delivery system that uses a voltage gradient to increase skin permeability, allowing for effective NAD+ absorption. The latex ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The global landscape of neurological health is undergoing a transformative moment with a pioneering nasal spray that could potentially revolutionize Alzheimer‘s disease management. As ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.